News & Media

Read about our latest news and initiatives, and find more information about Acadia. 

About Acadia

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders.

Assets & Materials

Contacts

Media

Acadia Contact

Deb Kazenelson

Phone

(818) 395-3043

Investors

Acadia Contact

Jessica Tieszen

Phone

(619) 322-5969

Investors

Acadia Contact

Al Kildani

Phone

(858) 261-2872